9月14日，美敦力盘前上涨3.23%，报93.75美元/股，成交额36.88万美元。
消息面上，伯恩斯坦将美敦力目标价从105美元上调至112美元，维持跑赢大盘评级。此前瑞银、Needham、BTIG等多家机构已相继上调目标价，当前市场均价约104美元，反映出分析师对公司前景的一致看好。此外，美敦力近日宣布换股要约方案，以至多7%的折价收购MiniMed股份，上限为每股美敦力兑换4.5939股MiniMed，显示其在糖尿病业务分拆后仍积极推进资本运作。基本面上，美敦力此前公布的2027财年Q1业绩超预期，营收同比增长13.8%至97.6亿美元，心血管业务大增18.9%，并上调全年EPS指引至5.94-6.00美元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.